Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
http://img.marketwire.com/rss/mwPBES.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
angle plc  announced  announces  clinical  company  dec  december  drug  marketwired dec  marketwired december  marketwired  new  sales 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies



Marketwired - Equipment and Supplies



Last Build Date: Wed, 13 Dec 2017 08:32:03 EST

Copyright: Copyright: (C) Marketwired
 



Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018

Wed, 13 Dec 2017 08:00:00 EST

TORONTO, ONTARIO--(Marketwired - Dec. 13, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the company has entered into a distribution agreement with CASTER MEDICAL SYSTEM ("CMS") to launch ToraymyxinT ("PMX") and EAAT in Canada commencing in the first quarter of 2018. CMS's experienced sales team will promote the products in all parts of the country, with Spectral's team contributing scientific and marketing support. CMS is specialized in selling high value medical devices (disposables and capital equipment), including a non-invasive cardiac monitoring system that can be used to monitor PMX treatment effectiveness in improving patient cardiovascular function.




Optimize Patient Enrollment by Incorporating Physician Referral Networks in Your Outreach Plan, New Webinar Hosted by Xtalks

Wed, 13 Dec 2017 07:30:00 EST

TORONTO, ON--(Marketwired - December 13, 2017) - In a webinar upcoming on Tuesday, January 9, 2018, a panel of physicians and clinical site experts will discuss the various clinical trial stakeholders and the traditional interactions they have with referring physicians. They will share how these efforts can meet their full potential by leveraging proven referring physician outreach models and the key tactics within those.




Relevium Strengthens its Balance Sheet: Long-term Debt Down by $900,000, Cash Increases by Over $1,100,000

Tue, 12 Dec 2017 07:00:00 EST

MONTREAL, QUEBEC--(Marketwired - Dec. 12, 2017) - Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the "Company" or "Relevium"), is pleased to announce it has strengthened its balance sheet through the partial conversion of debentures into equity, and increased its cash position through the exercise of warrants and options. The Company is also pleased to provide an update on the Non-Binding Letter of Intent ("LOI") announced October 25, 2017.




Angle PLC: Transfer of Lock-in Shares

Tue, 12 Dec 2017 02:00:00 EST

GUILDFORD, SURREY--(Marketwired - Dec 12, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)




Rennova Health Announces an Upgrade of MedicalMime's Flagship EHR M2Select to Version 3.3

Mon, 11 Dec 2017 09:20:00 EST

WEST PALM BEACH, FL--(Marketwired - December 11, 2017) - Rennova Health, Inc. (OTCQB: RNVA) (OTCQB: RNVAW) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that opened its first rural hospital in Oneida, Tenn. on August 8, 2017, announces an upgrade of its flagship electronic health records (EHR) platform, M2Select to Version 3.3. This platform is available to office-based physicians, as well as to mental health providers working in substance abuse and drug and alcohol rehabilitation facilities.




Radient Technologies Inc. Announces Master Services Agreement with Terra Life Sciences

Mon, 11 Dec 2017 07:00:00 EST

EDMONTON, ALBERTA and CALGARY, ALBERTA--(Marketwired - Dec. 11, 2017) - Radient Technologies Inc. ("Radient" or the "Corporation") (TSX VENTURE:RTI) announces the signing of a Master Services Agreement (the "Agreement") to produce cannabis extracts for the Terra Life Sciences group ("Terra Life Sciences"), a private, Alberta-based pharmaceutical manufacturer whose ACMPR license is expected in the near future.




ANGLE plc Announces Parsortix Potential in Metastatic Breast Cancer

Fri, 08 Dec 2017 02:00:00 EST

GUILDFORD, SURREY--(Marketwired - Dec 8, 2017) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




UltraSPECT's New Ultra-Secured Gateway Delivers Impenetrable Defense Against Cybercriminals Seeking to Breach Nuke Med Systems

Thu, 07 Dec 2017 09:43:53 EST

Military-grade 'USG' gateway ensures airtight data security for users of UltraSPECT's popular image-reconstruction solution




ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018

Thu, 07 Dec 2017 08:42:32 EST

LOS ANGELES, CA--(Marketwired - December 07, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment Vitastem. ViaDerma will work with a new sales and marketing group to put 25 sales representatives on the ground selling ViaDerma's products to networks of Hospitals and directly to physicians' offices. The projected revenues for 2018 from this initiative should generate $6.9 million dollars.




Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402

Thu, 07 Dec 2017 08:30:00 EST

BOSTON, MA--(Marketwired - December 07, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to initiate its first-in-human study in Australia for PRS-060/AZD1402, an inhaled Anticalin protein that targets IL-4R? for the treatment of moderate to severe asthmatic patients that are not controlled on standard of care. This phase 1 study will be conducted in healthy subjects and is being developed as part of Pieris' strategic alliance with AstraZeneca, which is funding the trial, with Pieris being responsible for conducting the study.




Moleculin's WP1066 Drug receives $2 million Private Grant

Wed, 06 Dec 2017 10:01:00 EST

HOUSTON, TX--(Marketwired - December 06, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced that its WP1066 drug will receive $2 million in private grant funding for its recently announced Investigational New Drug ("IND") clearance for a physician-sponsored Phase I trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.